Scopus BioPharma (Nasdaq: SCPS) is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.
Our lead development program, CO-sTiRNA, is a novel, targeted immuno-oncology gene transfer for the treatment of multiple cancers. Our second lead development program, MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.
Press Releases
Scopus BioPharma Announces Appointment of Additional Directors
December 29, 2020
Scopus BioPharma Announces Closing of Initial Public Offering
December 18, 2020
Scopus BioPharma Announces Pricing of Initial Public Offering
December 15, 2020
Pipeline
Program
Drug Candidate
Pre-Clinical Testing
IND-Enabling Studies
Phase 1
Gene Therapy
CO-sTiRNA
B-cell Non-Hodgkin's Lymphoma
CO-sTiRNA
+
Checkpoint Inhibitors
and/or
CAR-Ts
B-cell Non-Hodgkin's Lymphoma
Cutaneous T-cell Lymphoma
Other Solid Tumors
CB1R Inverse Agonists
MRI-1867
Systemic Sclerosis